Small Molecule Therapies for CMT
Small molecule therapies typically are developed from simple building blocks or are derived from natural sources. With their small size, they are easily able to pass through the cell membrane and access targets inside the cell.
Small molecule drugs are designed to modify a disease process via regulation of a biological target such as an enzyme, channel or receptor. They make up the majority of today’s drug treatments and may be used alone or as individual elements in combination therapies.
CMT Research Foundation is leading the charge to ensure safe and effective therapies for all forms of CMT make it to the market to help those living with CMT today. We are working every day to support the families, the foundations, the academics, the scientists, the biotechs and the pharma companies who share our goal and who are working to make it happen.
Related News & Research
Inaugural Zero-K Run Raises Awareness for CMT and CMTRF
When many people think of the word “race” they imagine a 5k, 10k and even a half-marathon. But, what about a new type of run that directly benefits patients with Charcot-Marie-Tooth disease and covers no distance at all—A Zero-K Run. A Zero-K Run is exactly what it...
The CMT Research Foundation’s 2024 Global CMT Research Convention to Gather Renowned Scientific Experts and Patients to Discuss Status of Treatments and Cures for Charcot-Marie-Tooth (CMT) Disease
The CMT Research Foundation recently announced most of the speakers at its upcoming 2024 Global CMT Research Convention to be held September 26-28, in Cambridge, MA. On Thursday, September 26, CMTRF will host a Young Researcher Innovation Forum for CMT Research....
CMT Research Foundation to Launch Grant Program to Support Young Investigators Working on CMT
The CMT Research Foundation announced that at its annual Global CMT Research Convention this September, it will host a Young Researcher Innovation Forum for CMT Research. The program will introduce the Young Researcher Innovation Grant and provide a platform to...
Augustine Therapeutics Raises $18.5 Million in a Series A First Closing
The Charcot-Marie-Tooth Research Foundation participated in the $18.5 million Series A funding round recently announced by Augustine Therapeutics. The financing was led by Asabys Partners, with the participation of Eli Lilly & Company, CMTRF, and current investors...
CMT Research Foundation Invests in ReviR Therapeutics Research to Pioneer Small Molecule Therapeutics for CMT1A
The CMT Research Foundation has formed a strategic partnership with ReviR Therapeutics to advance small molecule therapeutics that modulate the expression of the gene that causes CMT1A. ReviR Therapeutics is developing a class of drugs called small molecule splice...
NMD Pharma Receives FDA Clearance to Initiate Clinical Trial of NMD670 for CMT
NMD Pharma recently announced that it has received clearance from the US Food and Drug Administration (FDA) for its Investigational New Drug (IND) application to initiate a Phase 2 clinical trial of NMD670 in patients living with CMT types 1 and 2.NMD670 is a...
CMT Research Foundation to Benefit from a Portion of Ticket Sales from Alan Jackson’s 2024-2025 LAST CALL: ONE MORE FOR THE ROAD TOUR
The CMT Research Foundation (CMTRF), the only nonprofit organization focused solely on delivering treatments and cures for Charcot-Marie-Tooth disease* (CMT), is pleased to announce support from Alan Jackson's LAST CALL ONE MORE FOR THE ROAD TOUR 2024-2025 dates....
CMTRF at the 2024 American Society of Gene and Cell Therapy Conference
We are thrilled to see that two CMTRF-funded projects were selected to present their advancements on their CMT gene therapy projects at the ASGCT conference, the premier conference for emerging genetic therapies.Dr. Lindsay Wallace presented a poster on the CMT1A gene...
Walking Manhattan to Find a Cure
From a young age, Rivka knew that there was something different about her compared to her three siblings; that difference was Charcot-Marie-Tooth (CMT) disease.Meet Rivka Ligier, a CMT1B patient who is preparing to participate in this year's Great Saunter, a one-day,...
CMT Research Foundation Invests in Project to Test if a Commercially Available Drug is Effective Treatment for X-linked Charcot-Marie-Tooth Disease
The CMT Research Foundation (CMTRF), a non-profit focused solely on delivering treatments and cures for Charcot-Marie-Tooth disease (CMT), has invested in a project led by Dr. Charles Abrams, a Professor in the Department of Neurology and Rehabilitation at the...
Address
4062 Peachtree Road
Suite A209
Atlanta, GA 30319
Phone Number
404.806.7180